Trial Profile

An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary) ; RP 2 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Uveal melanoma
Focus Adverse reactions; First in man
Sponsors Replimune

Most Recent Events

04 Jun 2024 Safety, efficacy, and biomarker results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
03 Jun 2024 According to a Replimune media release, data from this trial presented at the 2024 American Society of Clinical Oncology (ASCO)
03 Jun 2024 Results published in the Replimune Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com